Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, and Rockville, MD, USA, October 27, 2022 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that they
Pratteln, Switzerland, October 3, 2022 - Santhera Pharmaceuticals (SIX: SANN) announces that the Company has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA)
Results from the VISION-DMD study showing efficacy and safety of vamorolone compared to placebo and to standard of care, prednisone, has been published in.
Results from the VISION-DMD study showing efficacy and safety of vamorolone compared to placebo and to standard of care, prednisone, has been published in JAMA Neurology (https://jamanetwork.com/journals/jamaneurology/fullarticle/2795868?utm campaign=articlePDF&utm medium=articlePDFlink&utm source=articlePDF&utm content=jamaneurol.2022.2480)Safety